GLP-1s Linked to Lower Risk of Cancer Spread in Four Tumor Types
MedPage Today • • health
Key Points:
- A propensity score-matched analysis found that GLP-1 receptor agonist use in patients with stage I-III colorectal, liver, breast, or lung cancers was linked to a 31% to 50% lower risk of progression to metastatic disease over five years compared to those using DPP-4 inhibitors.
- For prostate, pancreatic, and kidney cancers, GLP-1 drug users showed numerically lower progression rates to metastatic disease, but these differences were not statistically significant.
- Experts caution that despite promising observational data, it is too early to prescribe GLP-1 drugs specifically to slow cancer progression, emphasizing the need for prospective randomized trials to confirm causation.
- The study analyzed data from 10,225 patients using GLP-1 drugs after cancer diagnosis, matched with 12,112 patients on DPP-4 inhibitors, adjusting for confounders but noting limitations in the TriNetX database used.
- Additional analysis showed that high GLP-1 receptor expression in tumors was associated with a significantly lower risk of death, suggesting a potential biological mechanism behind the observed clinical benefits.